News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

May 20, 2009
GW Pharmaceuticals plc (GWP:AIM) today announces that it has filed a regulatory submission for Sativex for the treatment of spasticity due to Multiple Sclerosis.
Apr 01, 2009
GW Pharmaceuticals plc (GWP:AIM) today announces that it has received confirmation from its licensing partner, Laboratorios Almirall S.A., that it will pay to GW a milestone payment of GBP 8 million.
Mar 11, 2009
GW Phase III Spasticity Results - Analyst Presentation GW Pharmaceuticals plc hosted todays Phase III Spasticity Results Analyst Presentation on Wednesday 11th March 2009 at 2:30pm.
Mar 11, 2009
GW Pharmaceuticals plc (GWP:AIM) today announces positive preliminary results from a pivotal Phase III double-blind randomised placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosi
Feb 24, 2009
GW Pharmaceuticals plc (GWP:AIM) announces positive results from a placebo-controlled randomized withdrawal study of Sativex® in patients with spasticity due to Multiple Sclerosis (MS).

Pages